Matti Isohanni
Overview
Explore the profile of Matti Isohanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
2880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Konttajarvi T, Haapea M, Huhtaniska S, Bjornholm L, Miettunen J, Isohanni M, et al.
Psychiatry Res Neuroimaging
. 2024 Feb;
339:111790.
PMID: 38354478
Exposure to antipsychotics as well as certain first-episode illness characteristics have been associated with greater gray matter (GM) deficits in the early phase of schizophrenia. Whether the first-episode illness characteristics...
2.
Grasa E, Seppala J, Alonso-Solis A, Haapea M, Isohanni M, Miettunen J, et al.
JMIR Form Res
. 2023 Jun;
7:e46179.
PMID: 37389933
Background: In the European Union, around 5 million people are affected by psychotic disorders, and approximately 30%-50% of people with schizophrenia have treatment-resistant schizophrenia (TRS). Mobile health (mHealth) interventions may...
3.
Seppala A, Pylvanainen J, Lehtiniemi H, Hirvonen N, Corripio I, Koponen H, et al.
Schizophr Res
. 2021 Sep;
236:123-134.
PMID: 34496316
Background: As the burden of treatment-resistant schizophrenia (TRS) on patients and society is high it is important to identify predictors of response to medications in TRS. The aim was to...
4.
Lieslehto J, Jaaskelainen E, Kiviniemi V, Haapea M, Jones P, Murray G, et al.
NPJ Schizophr
. 2021 Jun;
7(1):32.
PMID: 34127678
Age plays a crucial role in the performance of schizophrenia vs. controls (SZ-HC) neuroimaging-based machine learning (ML) models as the accuracy of identifying first-episode psychosis from controls is poor compared...
5.
Alonso-Solis A, Ochoa S, Grasa E, Rubinstein K, Caspi A, Farkas K, et al.
Int J Environ Res Public Health
. 2020 Oct;
17(20).
PMID: 33081208
Introduction: Community services are gaining ground when it comes to attention to patients with psychiatric diseases. Regarding patients with treatment-resistant schizophrenia (TRS), the use of information and communication technology (ICT)...
6.
Miller B, Herzig K, Jokelainen J, Karhu T, Keinanen-Kiukaanniemi S, Jarvelin M, et al.
Eur Arch Psychiatry Clin Neurosci
. 2020 May;
271(4):609-622.
PMID: 32382794
Increased blood interleukin-6 (IL-6) levels are a replicated abnormality in schizophrenia, and may be associated with smaller hippocampal volumes and greater cognitive impairment. These findings have not been investigated in...
7.
Korpela H, Miettunen J, Rautio N, Isohanni M, Jarvelin M, Jaaskelainen E, et al.
Eur Psychiatry
. 2020 Mar;
63(1):e24.
PMID: 32146919
Background: We studied the cumulative incidence of physical illnesses, and the effect of early environmental factors (EEFs) on somatic comorbidity in schizophrenia, in nonschizophrenic psychosis and among nonpsychotic controls from...
8.
Seppala J, De Vita I, Jamsa T, Miettunen J, Isohanni M, Rubinstein K, et al.
JMIR Ment Health
. 2019 Feb;
6(2):e9819.
PMID: 30785404
Background: Mobile Therapeutic Attention for Patients with Treatment-Resistant Schizophrenia (m-RESIST) is an EU Horizon 2020-funded project aimed at designing and validating an innovative therapeutic program for treatment-resistant schizophrenia. The program...
9.
Huhtaniska S, Korkala I, Heikka T, Bjornholm L, Lehtiniemi H, Hulkko A, et al.
Psychiatry Res Neuroimaging
. 2018 Sep;
281:43-52.
PMID: 30219591
The aim of this paper was to investigate differences in brain structure volumes between schizophrenia and affective psychoses, and whether cumulative lifetime antipsychotic or benzodiazepine doses relate to brain morphology...
10.
Alonso-Solis A, Rubinstein K, Corripio I, Jaaskelainen E, Seppala A, Vella V, et al.
BMJ Open
. 2018 Jul;
8(7):e021346.
PMID: 30012788
Introduction: Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms...